TD Asset Management
LXRX icon

TD Asset Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

TD Asset Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-8,400
Closed -$139K – 1302
2013
Q3 		$139K Hold
8,400
– – ﹤0.01% 1229
2013
Q2 		$128K Buy
+8,400
New +$128K ﹤0.01% 1163

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

TD Asset Management's LXRX Position: Q4 2013 in Review

TD Asset Management sold out of Lexicon Pharmaceuticals (LXRX) in Q4 2013, closing a stake of 8,400 shares — an estimated $139K sold.

TD Asset Management first reported a position in LXRX in Q2 2013 and held it in 2 quarters. The position peaked at $139K in Q3 2013. 109 funds tracked by Wall St. Rank hold LXRX as of Q4 2013.

  • TD Asset Management reported no remaining Lexicon Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • TD Asset Management sold 8,400 Lexicon Pharmaceuticals shares in Q4 2013, an estimated $139K.
  • TD Asset Management first reported a position in Lexicon Pharmaceuticals in Q2 2013 and held it in 2 quarters.
  • TD Asset Management's Lexicon Pharmaceuticals position peaked at $139K in Q3 2013.
  • 109 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q4 2013.

Based on TD Asset Management's 13F filing for Q4 2013, filed 7 Feb 2014.